Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PulmoStem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the study is to evaluate the safety and tolerability of intravenous dosing of PulmoStem (amniopul-02) in patients with severe lower respiratory tract infections, including COVID-19, Influenza A, Metapneumovirus and Respiratory Sy...
Product Name : PulmoStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : PulmoStem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PulmoStem
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $6.9 million
Deal Type : Public Offering
Amniotics Raises SEK 60 Million in First North IPO to Advance Lead Candidate PulmoStem™ Into Clinic
Details : The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled...
Product Name : PulmoStem
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 07, 2021
Lead Product(s) : PulmoStem
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $6.9 million
Deal Type : Public Offering